© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Persistent Underutilization of Systemic Therapy for Atopic Dermatitis Highlights Gap Between Need and Care
June 09, 2025
RAD 2025: Mobile health data reveal a troubling decline in systemic treatment for moderate to severe atopic dermatitis, underscoring issues in access and clinical inertia.
Dupilumab Monotherapy Improves AD Severity and Pigmentation in People With Skin of Color
June 09, 2025
Dupilumab monotherapy showed significant improvements in atopic dermatitis symptoms in patients with skin of color, according to late-breaking data presented at RAD 2025.
Long-Term Data on Nemolizumab Demonstrate Safety, Sustained Symptom Improvement in Patients With Atopic Dermatitis up to 2 Years
June 09, 2025
RAD 2025: Adults and adolescents treated with nemolizumab experienced rapid onset of action and robust improvements in pruritis, sleep, and quality of life up to 2 years.
Mona Shahriari, MD: Explore the Psychosocial Burden of Atopic Dermatitis with Your Patients—Ask Questions
June 07, 2025
RAD 2025: Mona Shahriari, MD, underscored the cumulative life impact of atopic dermatitis, reminding clinicians that there is always far more to the condition than meets the clinical eye.
Ruxolitinib Cream Demonstrates Long-Term Safety and Disease Control in Young Patients With Atopic Dermatitis
June 06, 2025
RAD 2025: In the TRuE-AD3 study, participants aged 2-6 and 7-11 years spent nearly half of the long-term treatment period free of medication.
Nemolizumab Improves Pruritis, Sleep Within 2 Days When Added to Standard Topical Therapy for Atopic Dermatitis
June 06, 2025
RAD 2025: Nemolizumab as adjunctive therapy to topical steroids with/without topical calcineurin inhibitors provided rapid relief in moderate-to-severe atopic dermatitis.
Dupilumab Sustains Long-Term Reduction of Staphylococcus aureus in Patients with Atopic Dermatitis
June 06, 2025
RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.
INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis
June 06, 2025
RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.
Lebrikizumab Maintains Deep Response, QoL Through 3 Years in Atopic Dermatitis Extension Study
June 06, 2025
RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.
Roflumilast Cream 0.15% Demonstrates Safety, Tolerability in Individuals With Atopic Dermatitis With Prior Treatment Failures
June 06, 2025
RAD 2025: Safety and tolerability of roflumilast cream 0.15% was demonstrated in a pooled subgroup analysis of phase 3 study participants unresponsive to or intolerant of previous topical therapy.